Drugs & Pharmaceuticals

Gilead Science is the Tom Brady of the antiviral research world. No other company even comes close.

The first discussion of the disease that would later become AIDS appeared in an article in the June 5, 1981 Morbidity and Mortality Weekly Report (MMWR).

Last week, Tom Frieden, the former Director of the US Centers for Disease Control in the Obama administration, wrote an editorial in the

Stat News just broke a story that has been picked up by the wider press and has generated quite a bit of

# From The Latest Hydroxychloroquine Data, As of April 11.

In spite of study after study and the writings of expert after expert over the last 25 years, we, as a society, have failed to provide for our own security in the face of a potential public health threat.  We have failed to supply and ma

It is rare to find a mention of Giliead's remdesivir, arguably the most promising drug in the fight against coronavirus, without also hearing that it failed miserably in fighting Ebola.

Press briefings, by any measure, are long and loud. And now they may get longer and louder since there is another potential antiviral drug to yell about. 

I thought that this would be a good time to review the various vaccines and therapies being studied to combat the coronavirus pandemic.

By Katherine Seley-Radtke, University of Maryland, B